Details

Autor(en) / Beteiligte

• Gyamfi-Bannerman, Cynthia
• Thom, Elizabeth A
• Blackwell, Sean C
• Tita, Alan T.N
• Reddy, Uma M
• Saade, George R
• Rouse, Dwight J
• McKenna, David S
• Clark, Erin A.S
• Thorp, John M
• Chien, Edward K
• Peaceman, Alan M
• Gibbs, Ronald S
• Swamy, Geeta K
• Norton, Mary E
• Casey, Brian M
• Caritis, Steve N
• Tolosa, Jorge E
• Sorokin, Yoram
• VanDorsten, J. Peter
• Jain, Lucky

Titel

Antenatal Betamethasone for Women at Risk for Late Preterm Delivery

Ist Teil von

• The New England journal of medicine, 2016-04, Vol.374 (14), p.1311-1320

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• In this multicenter, randomized trial involving women at high risk for late preterm delivery, administration of betamethasone significantly reduced the rate of neonatal respiratory complications. Antenatal glucocorticoids are widely used in obstetrics for pregnancies at risk for early preterm delivery. Their use increased especially after a consensus conference held by the National Institutes of Health in 1994, which concluded that there was strong evidence that glucocorticoids reduce adverse neonatal outcomes, including death, the respiratory distress syndrome, and other complications, when administered to women who are likely to deliver before 34 weeks of gestation. 1 – 3 The recommendation was not extended to women at risk for preterm delivery after 34 weeks because of both a lack of data 4 , 5 and the belief that at a threshold of . . .